Amylyx Pharmaceuticals to remove ALS drug from US, Canada markets-March 2024-www.financetom.com

Amylyx Pharmaceuticals to remove ALS drug from US, Canada markets

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Amylyx Pharmaceuticals to remove ALS drug from US, Canada markets

Apr 4, 2024 4:38 AM

April 4 (Reuters) - Amylyx Pharmaceuticals ( AMLX ) said

on Thursday it would withdraw its amyotrophic lateral sclerosis

(ALS) drug from the U.S. and Canada markets after the treatment

failed in a crucial late-stage trial.

Previous page： Google agrees $36 million fine for anti-competitive deals with Australia telcos Next page： F5 Fiscal Q3 Non-GAAP Earnings, Revenue Rise; Shares Jump After Hours

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Google agrees $36 million fine for anti-competitive deals with Australia telcos

Aug 17, 2025

SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...

F5 Fiscal Q3 Non-GAAP Earnings, Revenue Rise; Shares Jump After Hours

Jul 30, 2025

05:09 PM EDT, 07/30/2025 (MT Newswires) -- F5 (FFIV) reported fiscal Q3 non-GAAP earnings late Wednesday of $4.16 per diluted share, up from $3.36 a year earlier. Analysts polled by FactSet expected $3.51. Revenue in the three months ended June 30 rose to $780.4 million from $695.5 million a year earlier. Analysts surveyed by FactSet expected $753.9 million. The company...

Commercial real estate lender Timbercreek's Q2 net income falls

Jul 30, 2025

Overview * Timbercreek Q2 net income declines to C$12.4 mln from $15.4 mln yr/yr * Net mortgage investment portfolio grows C$34.8 mln from Q1 2025 * Net investment income decreases to C$25.2 mln from C$26.4 mln yr/yr Outlook * Company expects multi-family residential to perform well amid economic uncertainty Result Drivers * INTEREST RATE FLOORS - High percentage of variable...

Airbus faces engine delays but reaffirms jet delivery targets

Jul 30, 2025

* Airbus says faces gaps in engine supply from Pratt & Whitney * Delay comes on top of gaps in supplies from engine maker CFM * Airbus burns cash but posts higher profit in second quarter * Now expects Spirit Aero deal to close in fourth quarter (Recasts after media and analyst calls, adds context) By Tim Hepher PARIS, July...